PT - JOURNAL ARTICLE AU - Oh, C. K. AU - Geba, G. P. AU - Molfino, N. TI - Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma AID - 10.1183/09059180.00007609 DP - 2010 Mar 01 TA - European Respiratory Review PG - 46--54 VI - 19 IP - 115 4099 - https://publications.ersnet.org//content/19/115/46.short 4100 - https://publications.ersnet.org//content/19/115/46.full SO - EUROPEAN RESPIRATORY REVIEW2010 Mar 01; 19 AB - Asthma is a complex, persistent, inflammatory disease characterised by airway hyperresponsiveness in association with airway inflammation. Studies suggest that regular use of high-dose inhaled corticosteroids and long-acting bronchodilators or omalizumab (a humanised monoclonal antibody that binds to immunoglobulin E and is often used as next-step therapy) may not be sufficient to provide asthma control in all patients, highlighting an important unmet need. Interleukin-4, interleukin-13, and the signal transducer and activator of transcription factor-6 are key components in the development of airway inflammation, mucus production, and airway hyperresponsiveness in asthma. Biological compounds targeting these molecules may provide a new therapeutic modality for patients with uncontrolled severe asthma. The purpose of this review is to summarise current studies of compounds targeting the interleukin-4/interleukin-13 pathway and to provide a rationale for the development of such compounds for this use.